Rtef-1 variants and the use thereof for inhibition of...

Details Rtef-1 variants and the use thereof for inhibition of... Rtef-1 variants and the use thereof for inhibition of...

C - Chemistry, Metallurgy

07

K

C07K 14/435 (2006.01)

Patent

CA 2689913

Dominant negative (DN) variants of transcriptional enhancer factor 1- related (RTEF-I) are described. DN RTEF-I polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-I may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).

L'invention concerne des variants dominants négatifs (DN) du facteur-1 d'amélioration de transcription associé (RTEF-I). Les polypeptides DN du RTEF-I sont susceptibles de cibler directement des cellules ou d'être amenés dans des vecteurs d'expression d'acides nucléiques afin d'altérer la transcription cellulaire. L'invention concerne des procédés destinés à inhiber la production de VEGF et, de la sorte, à traiter des troubles angiogéniques tels que le cancer. Par exemple, dans certains aspects, les DN du RTEF-I peuvent être utilisés pour traiter des troubles angiogéniques de l'il tels que la dégénération maculaire liée à l'âge (DMA).

Affiliated with

Also associated with

Rating

Rtef-1 variants and the use thereof for inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rtef-1 variants and the use thereof for inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rtef-1 variants and the use thereof for inhibition of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2004911